Abstract: A tamper resistant drug delivery system made of at least one lipid, at least one gelling agent and at least one drug active, such as oxycodone, where the system gels rapidly in the presence of water or a solution containing water, and the drug active releases into the digestive system, wherein the weight ratio of gelling agent to lipid is less than 1:1.4.

Abstract: An object of the present invention is to provide a transdermal absorption enhancer by which various active ingredients are transdermally absorbed. In accordance with a transdermal absorption enhancer of the present invention which effective ingredient is lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, transdermal absorption of a macromolecular substance and a water-soluble substance was able to be improved.

Abstract: A delivery system for a hygienic agent according to the present invention includes an agent in a viscous paste and/or semi-solid gel form, which includes a skin benefiting composition containing cleansing and/or positive skin sensory elements. The system is configured to deliver the skin benefiting composition to the whole body or on selected, discrete parts of the body to promote a skin massaging/pleasant feel, during either a washing process or outside of a washing process.

Abstract: The invention provides aqueous concentrates comprising, based on the total composition, A) 0.1 to 8.0% by weight, preferably 3.0 to 7.0% by weight, of one or more isethionates of formula (1) RCOOCH2CH2SO3M ??(1) in which R is a linear or branched alkyl group or alkenyl group and M is a counterion, B) 0.1 to 8.0% by weight of one or more taurates of formula (2) R1CON(CH3)CH2CH2SO3X ??(2) in which R1 and X have the same meaning as R and M and C) 0.1 to 40.0% by weight of one or more alkylbetaines of formula (3) in which R2 has the same meaning as R, with the proviso that the concentration of the sum of all surfactants with the formula 1, 2 and 3 is more than 20% by weight. These concentrates are flowable at room temperature and are transparent and also colorless.

Abstract: Disclosed are bupivacaine transdermal delivery systems, and related methods.

Abstract: A surfactant of formula 1 (Rf-A)a-Q-([B]k—R)b??Formula 1 wherein a and b are each independently 1 or 2; Rf is a linear or branched perfluoroalkyl radical having from 2 to about 20 carbon atoms, optionally interrupted with at least one oxygen; R is a C1 to C20 linear, branched or cyclic alkyl, or a C6 to C10 aryl; B is —(CH2CHR1O)x—, k is 0 or 1, x is 1 to about 20, A is —(CH2)m[(CHR1CH2O)]s—[(CH2)m(CH)tCHOH(CH2)m]e—, wherein each m is independently 0 to 3, s is 0 to about 30, t is 0 or 1, and e is 0 or 1, R1 is H or CH3, Q is: —OP(O)(O?M+)(O)—, —O—, —S—(CH2)m—C(O)—O—, —SO2—O— —CH2CH2O—C(O)CH2C(OH)(V)CH2C(O)O—; —(CH2CH2O)xCH2CH(OH)—(CH2CH2O)x—(CH2)m—Si[OSi(R2)3]2—, —SO2NR2—, —(CH2CH2O)zC(O)CH(SO3?M+)CH2C(O)(OCH2CH2)z— wherein z is 1 to about 15, or a bond when s is a positive integer, V is —C(O)OR3 and R3 is H, CH3 or Rf; R2 is C1 to C4 alkyl, and M+ is a Group 1 metal or an ammonium (NHxR2y)+ cation wherein x+y=4, and R2 is C1 to C4 alkyl, provided that when Q is —OP(O)(O?M+)(O)— or when Q is —(

Abstract: Onychomycosis is treated by grinding the infected portion of a nail down to a level where the nail is not infected and applying a coating of a cyanoacrylate ester to the ground portion which cures to a hard layer. The hard layer can be successively ground and coated with successive layers of cycanoacrylate.

Abstract: The invention provides compositions and methods for increasing cell growth, stimulating cell turnover and promoting the secretion of mucus within the reproductive tract of a female mammal.

Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Abstract: Pigment wetting agent contains a mixture of monoesters and diesters of butylene glycol and fatty acids.

Abstract: The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot that releases the pharmaceutically active compound over time. The pharmaceutical compositions can also be administered orally.

Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.

Abstract: A surfactant composition contains at least one sorbitan ester and at least one sorbitol ester wherein the mean number of carbon atoms of the hydrophobe of the sorbitan ester is greater than that of the sorbitol ester. The surfactant composition is particularly suitable for use in stabilising emulsions, especially personal care or cosmetic products.

Abstract: Provided are compositions comprising a depilatory active; and a surfactant, wherein the composition has a Yield Stress of from about 1 Pascal (Pa) to about 1500 Pa, and methods of use thereof.

Abstract: Gelling agents which contain a specific N-acylamino acid monoamide monoalkyl ester have a melting temperature of about 100° C., are capable of solidifying a wide variety of oily base materials including silicones, and do not cause “sweating” while retaining a practical level of gel strength. When applied to skin, the resulting gels have a good feeling, good spreadability, and good fittability to skin.

Abstract: The invention relates to clear, liquid preservatives, which contain a) one or several 1-hydroxy-4-methyl-6-alkyl-2(1H)-pyridones and/or one or several salts thereof. wherein alkyl represents a linear, branched or cyclic alkyl group having 1-12 carbon atoms, and b) one or several alcohols containing one or several aromatic groups.

Abstract: The present invention relates to the use of a lipidic phase comprising an oil and a lipophilic additive (LPA), which is suitable to make an oil-in-water emulsion by application of low energy or a manual operation. The lipidic phase contains a Lipophilic Additive (LPA) which forms self-assembly structures inside the emulsion oil droplets. The aqueous phase contains a hydrophilic emulsifier and the lipidic and aqueous phases are mixed without using classical high shearing devices or homogenisers.

Abstract: A chemically and physically stable, transparent, hybrid pesticide concentrate is provided for preparation of a water-based microemulsion formulation. The pesticides preferably comprise an oil-soluble pesticide component, and a pesticide component having a Lewis acid pesticide portion and a pesticide complex portion. An inactive biphasic coupling agent for the pesticide ingredients includes a solvent capable of solvating the oil-soluble pesticide component, and two organic cosolvents capable of solvating the Lewis acid pesticide portion and the pesticide complex portion pesticide ingredients, respectively. A selected emulsifier is incorporated in the concentrate. A sufficient quantity of a complexing agent is provided to maintain the electrical potential of the final concentrate at a value of about ?150 mV to about +150 mV.

Abstract: An encapsulated composition of (a) a pesticide at least active via ingestion that is photolabile, and (b) at least one photoprotectant, wherein the encapsulating polymeric barrier is base triggerable is disclosed. A method for controlling damage of a material by a pest by the use of such encapsulated compositions is likewise disclosed. The composition as disclosed gives protection for beneficial arthropods and reduces workers exposure.

Abstract: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

Abstract: The present invention is directed to a skin care composition comprising (a) at least one high internal phase emollient-in-water emulsion; (b) at least one fatty compound, capable of forming a liquid crystal; (c) at least one thickening agent; (d) at least one active agent; and (e) water. Also disclosed is a method of treating skin with the above-disclosed skin care composition.

Abstract: This invention relates to newly identified ester-linked gemini surfactant compounds, to the use of such compounds and to their production. The invention also relates to the use of the ester-linked gemini surfactant compounds to facilitate the transfer of polynucleotides into cells.

Abstract: Energy-reversible acyl conjugates, intermediates, and related compositions are disclosed.

Abstract: The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration.

Abstract: A base composition is provided which comprises water and a non-ionic surfactant mixture. The base composition is suitable for use in preparing a personal care product.

Abstract: A topical mixture, that when massaged onto the skin, enables infusion of drugs or herbal compounds into deeper tissues, and a method of enhancing the penetration and concentration of drugs and herbs into tissues, especially as relates to treatment of pain.

Abstract: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products.

Abstract: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products.

Abstract: The present invention relates to a wetting solution for manufacturing wet wipes or other wet flexible materials, and to such wet wipes for cosmetic, body care, dermatological and/or cleaning purposes, such as cleaning wipes, facial cleaning wipes, make-up remover wipes, refreshment wipes, baby wipes, wet toilet paper or eyeglass cleaning wipes, wherein the preferably aqueous wetting solution contains at least one amino acid ester, preferably from the group of pyrrolidone carboxylic acid esters, as an emulsifier. The invention further relates to the use of such amino acid esters as emulsifiers in wetting solutions for manufacturing said wet tissues.

Abstract: An oil material comprising a dimerdiol ester with a monocarboxylic acid having 4 to 34 carbon atoms or with a dimerdiol ester with a dicarboxylic acid; and a cosmetic and an external agent excellent in safety, stability, gloss, feeling and the like comprising the dimerdiol carboxylate.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10?7 reciprocal second.

Abstract: An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle.

Abstract: An object of the present invention is to provide a composition for external use in which the percutaneous absorbability of vitamin A, vitamin A derivative(s), vitamin C, specific vitamin C derivative(s), xanthine derivative(s), ubiquinone(s) and/or hyaluronic acid is improved. The composition for external use is prepared by blending (i) a phospholipid and (ii) a mono- or oligo-glycol ether, together with (iv) at least one bioactive component selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, vitamin A, vitamin A derivatives, vitamin C, specific vitamin C derivatives, xanthine derivatives, ubiquinones, and salts thereof.

Abstract: The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.

Abstract: Disclosed is a support, in particular for making topical cosmetic formulations comprising a mixture containing polyol esters with saturated linear acids and unsaturated linear and/or saturated branched acids, monounsaturated linear or saturated branched acid esters with saturated linear alcohols, saturated linear acid esters with monounsaturated linear or saturated branched alcohols, saturated linear and/or monounsaturated linear and/or saturated branched free alcohols, saturated linear ester acids and saturated linear alcohols, monounsaturated linear or saturated branched ester acids and monounsaturated linear or saturated branched linear alcohols, the linear saturated alcohols and acids having at least 20 carbon atoms and the monounsaturated or saturated branched alcohols and acids having at least 18 carbon atoms.

Abstract: Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail.

Abstract: The present invention relates to an emulsifier system comprising a) an ascorbic ester with long-chain fatty acids, b) an ethoxylated sorbitan fatty acid ester and c) a sugar fatty acid ester and emulsions prepared therewith.

Abstract: Surfactant systems are provided that, upon contact with an oil, can produce a Windsor Type III middle phase microemulsion at a total surfactant concentration of 1.5% to 1.0% or less based on the weight of water in the surfactant system, without the need for a cosolvent or linking molecule. The microemulsions can have a separation time less than about 2 hours and even less than about 15 minutes.

Abstract: The invention relates to the field of solid medicaments that are intended for the oral administration of active ingredients. The aim of the invention is to prevent the improper use of solid, oral medicaments for any user other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characturised in that it comprises: A) at least one caking agent; and B) at least one viscosifying agent, such as to prevent the misuse thereof.

Abstract: A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps.

Abstract: The blood collection, processing and transfer by separation of discrete components containing additional citrate (at least about trisodium citrate 9% w/v) in one or other of collection or processing bag provides for enhanced yield and purity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and plasma proteins and with the removal of the activated and denatured components thereby improving safety and efficacy of end products. The inventive process is particularly suited to an improved extraction process to yield concentrated clotting factors from single donors or limited pools without use of chromatography. Following extraction the remaining cryoprecipitate can advantageously be formed into a fibrin fabric used in surgeries and in the treatment of wounds.

Abstract: This invention relates to an agrochemical composition, comprising an anticrystallizing agent both in the concentrated formulation and after its dilution into water to prepare the spray broth. Said composition comprises (a) a pesticide, (b) a straight or branched chain, saturated or unsaturated fatty alcohol containing from 6 to 20 carbon atoms, (c) a straight or branched chain, saturated or unsaturated sulfonic acid and/or salts thereof, (d) a straight or branched chain, saturated or unsaturated ethoxylated fatty ester, and (e) an alkoxylate. This invention also relates to the use of this agrochemical composition and method for the application thereof.

Abstract: A process for preparing the drug-loaded cyanoacrylate nanoparticles is described. The cyanoacrylate nanoparticles which effectively deliver biological and therapeutic agents are synthesized by miniemulsion polymerization with surfactant, pluronic F127 or F68. Before initiation of polymerization, active agents with particularly highly hydrophobicity are dissolved in cyanoacrylate monomer. Compared with the drug-loaded polyalkylcyanoacrylate nanoparticles produced by emulsion polymerization, those produced by miniemulsion polymerization possess higher loading and encapsulation efficiencies. While the content of dissolved agents increases, furthermore, the loading and encapsulation efficiencies increase concurrently.

Abstract: The invention relates to a liquid concentrate for the preservation of cosmetic an pharmaceutical prod nets which comprises 3-iodo-2-propynyl butylcarbamate (IPBC), at least on liquid carrier selected from the group consisting of: polyvalent alcohols, glycol esters and glycol ethers, and at least one stabilizer selected from the group consisting of: formic acid, formic acid salts, and format esters, and comprising no additional carboxylic acid selected from the group consisting of: benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydroacetic acid and 10-undecylenic acid and a salt thereof being present.

Abstract: This invention relates to an improved formulation methodology for bioactive lipophilic molecules, such as Coenzyme Q10 (CoQ10) and its reduced analogs (ubiquinols). Further provided are methods of producing soft gel capsules of this formulation.

Abstract: The present invention relates to novel nonpolymeric compounds and compositions that form liquid, high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to form a material of lower viscosity, rendering the material easy to administer. This solvent may be water insoluble or water soluble, where the water soluble solvent rapidly diffuses or migrates away from the material in vivo, leaving a higher viscosity liquid material.

Abstract: Disclosed herein is an injectable composition for the treatment of cancers comprising a poorly water-soluble anti-cancer drug, and glycofurol and Solutol HS15 as solubilizer, of the anticancer drug.

Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) at least one neutral diacyl lipid, such as a diacyl glycerol; b) at least one phospholipid, such as a phosphatidyl choline; c) at least one biotolerable solvent, such as an oxygen containing solvent; d) at least one GLP-1 analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.

Abstract: An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated in a closed capsule assembly. The closed capsule assembly comprises the homeopathic carrier.

Abstract: The role of nanoparticle composition as biodegradable carriers for variously therapeutical drugs is disclosed. Nanoparticles are synthesized by anion emulsion polymerization of two alkyl-cyanoacrylate monomers with adjusted content ratio. By modulating the compositions, particle size, hydrophobicity and degradation rate of the copolymers is controlled. Hence, to encapsulate wide range of therapeutical drugs, poly(alkyl cyanoacrylate) nanoparticles with feasible compositions are applied individually. The copolymer nanoparticles produced by n-butyl cyanoactylate (BCA) and 2-octyl cyanoacrylate (OCA), for example, were used therein. The nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] and poly(2-octyl cyanoacrylate) might be adequate for therapeutical administration.